Albendazole induces the terminal differentiation of acute myeloid leukaemia cells to monocytes by stimulating the Krüppel‐like factor 4‐dihydropyrimidinase‐like 2A (KLF4‐DPYSL2A) axis
| Autor: | Yasuhiko Kamikubo, Souichi Adachi, Yoko Nishinaka-Arai, Mina Noura, Yukiko Okuno, Asami Koyama, Hiroki Kiyose, Ken Morita, Hidemasa Matsuo |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_treatment
Antineoplastic Agents Nerve Tissue Proteins Albendazole Monocytes Kruppel-Like Factor 4 Mice Differentiation therapy In vivo Cell Line Tumor hemic and lymphatic diseases medicine Animals Humans neoplasms Anthelmintics Chemotherapy business.industry Cell Differentiation Hematology In vitro Leukemia Myeloid Acute KLF4 Dihydropyrimidinase Cancer research Intercellular Signaling Peptides and Proteins business Platelet factor 4 Signal Transduction medicine.drug |
| Zdroj: | British Journal of Haematology. 194:598-603 |
| ISSN: | 1365-2141 0007-1048 |
| DOI: | 10.1111/bjh.17557 |
| Popis: | Differentiation therapy is a less toxic but still a very effective treatment for a subset of acute myeloid leukaemia (AML) cases. With the goal to identify novel compounds that can effectively and safely induce the terminal differentiation of non-acute promyelocytic leukaemia (APL) AML cells, we performed a chemical screening and identified albendazole (ABZ), a widely used anti-helminthic drug, as a promising lead compound that can differentiate non-APL AML cells by stimulating the Krüppel-like factor 4-dihydropyrimidinase-like 2A (KLF4-DPYSL2A) differentiation axis to the monocytes. Our in vitro and in vivo findings demonstrate that ABZ is an attractive candidate drug as a novel differentiation chemotherapy for patients with non-APL AML. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text